Overview

A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas

Status:
Completed

Trial end date:
2019-04-01

Target enrollment:

Participant gender:

Summary

This research study is investigating a drug called PM01183 alone and in combination with chemotherapy drugs called gemcitabine or doxorubicin as a possible treatment for metastatic or unresectable Sarcoma.

Phase:

Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborators:

Dana-Farber Cancer Institute
PharmaMar

Treatments:

Doxorubicin
Gemcitabine
Liposomal doxorubicin